Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga

Abhilash I. Chiramel, Logan Banadyga, Jonathan D. Dougherty, Darryl Falzarano, Cynthia Martellaro, Dominique Brees, R. Travis Taylor, Hideki Ebihara, Sonja M. Best

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


Antiviral therapeutics with existing clinical safety profiles would be highly desirable in an outbreak situation, such as the 2013-2016 emergence of Ebola virus (EBOV) in West Africa. Although, the World Health Organization declared the end of the outbreak early 2016, sporadic cases of EBOV infection have since been reported. Alisporivir is the most clinically advanced broad-spectrum antiviral that functions by targeting a host protein, cyclophilin A (CypA). A modest antiviral effect of alisporivir against contemporary (Makona) but not historical (Mayinga) EBOV strains was observed in tissue culture. However, this effect was not comparable to observations for an alisporivir-susceptible virus, the flavivirus tick-borne encephalitis virus. Thus, EBOV does not depend on (CypA) for replication, in contrast to many other viruses pathogenic to humans.

Original languageEnglish (US)
Pages (from-to)S355-S359
JournalJournal of Infectious Diseases
StatePublished - Oct 15 2016


  • Alisporivir
  • Antivirals
  • Cyclophilin A
  • Ebola virus
  • Flavivirus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases


Dive into the research topics of 'Alisporivir Has Limited Antiviral Effects Against Ebola Virus Strains Makona and Mayinga'. Together they form a unique fingerprint.

Cite this